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Summary
Background.  —  It  is  often  assumed  that  differences  in  the  efﬁcacy  of  treatments  between
countries  (or  regions)  will  be  neither  negligible  nor  minor  and  therefore  cannot  be  overlooked
when assessing  the  potential  beneﬁt  of  treatments  in  one  country  (or  region)  on  the  basis  of
trials conducted  in  another  country  (or  region).controlled  trials;
Treatment  efﬁcacy
Aim. —  To  assess  differences  in  the  results  of  cardiovascular  trials  between  Europe  and  North
America on  the  basis  of  data  from  an  extensive  collection  of  trials.
Methods.  —  A  systematic  search  was  conducted  of  Medline  (from  the  year  2005  to  2008)  and
the Cochrane  Library  (from  2000  to  2008)  for  all  meta-analyses  of  randomized  controlled  tri-
als aimed  at  treating  and  preventing  cardiovascular  disease.  Within  each  meta-analysis  that
Abbreviations: CVD, cardiovascular disease; RCT, randomized controlled trial.
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satisﬁed  given  criteria,  trial  results  were  compared  between  Europe  and  North  America  with
respect to  a  fatal  and/or  non-fatal  endpoint  by  forming  separate  estimates  of  treatment  efﬁcacy
for each  of  these  continents.
Results.  —  The  literature  search  found  59  meta-analyses  that  satisﬁed  all  the  inclusion  criteria.
For most  meta-analyses,  it  was  the  case  that  relative  to  the  control,  the  intervention  was  more
favoured in  trials  conducted  in  Europe  than  in  North  America  with  regard  to  both  fatal  endpoints
(28 out  of  43  meta-analyses)  and  non-fatal  endpoints  (28  out  of  40  meta-analyses).  However,  it
was only  with  regard  to  non-fatal  endpoints  that  this  imbalance  turned  out  to  be  statistically
signiﬁcant  at  the  5%  level  (P  =  0.017).  Also,  the  lack  of  statistically  signiﬁcant  differences  in  trial
results between  Europe  and  North  America  within  individual  meta-analyses  meant  that  it  was
not possible  to  determine  for  which  types  of  intervention  these  intercontinental  differences
are likely  to  be  more  pronounced  than  others.
Conclusion.  —  There  is  some  evidence  to  support  the  theory  that,  relative  to  controls,  inter-
ventions are  more  favoured  in  cardiovascular  trials  conducted  in  Europe  than  in  North  America,
when treatment  efﬁcacy  is  measured  in  terms  of  a  non-fatal  endpoint.  However,  the  overall
support for  systematic  differences  in  cardiovascular  trial  results  between  Europe  and  North
America is  weak,  which  may  be  surprising  given  the  amount  of  data  collected.
© 2014  Published  by  Elsevier  Masson  SAS.
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Résumé
Background.  —  Il  est  souvent  supposé  que  les  différences  dans  l’efﬁcacité  du  traitement  entre
les pays  ou  régions  ne  sont  ni  négligeables  ni  mineures,  et  donc  ne  devraient  pas  être  négligées
lorsque  l’on  évalue  les  bénéﬁces  potentiels  d’un  traitement  dans  un  pays  ou  une  région  sur  la
base d’essais  cliniques  conduits  dans  un  autre  traitement  ou  région  par  extrapolation.
Objectifs.  — Évaluer  les  différences  des  résultats  des  essais  cliniques  en  pathologie  cardiovas-
culaire entre  l’Europe  et  l’Amérique  du  Nord  sur  la  base  des  données  d’une  collection  extensive
des essais  cliniques  publiés.
Méthodes.  —  Une  recherche  systématique  a  été  conduite  sur  Medline  entre  2005  et  2008  et  sur  la
base Cochrane  entre  2000  et  2008  pour  toutes  les  méta-analyses  des  essais  contrôlés  randomisés,
ayant pour  objectif  de  traiter  ou  de  prévenir  une  pathologie  cardiovasculaire.  Au  sein  de  chaque
méta-analyse  satisfaisant  les  critères  déﬁnis,  les  résultats  des  essais  ont  été  comparés  entre
l’Europe et  l’Amérique  du  Nord  pour  ce  qui  concerne  le  critère  de  jugement  fatal  et/ou  non-
fatal, en  estimant  de  fac¸on  séparée  l’efﬁcacité  des  traitements  dans  chacun  des  continents.
Résultats. — La  recherche  effectuée  dans  la  littérature  a  trouvé  59  méta-analyses  satisfaisants
les critères  d’inclusion  de  l’étude.  Pour  la  majorité  des  méta-analyses,  il  a  été  vériﬁé  que
comparativement  aux  témoins,  l’intervention  était  plus  favorable  dans  les  essais  conduits  en
Europe, plutôt  qu’en  Amérique  du  Nord  pour  ce  qui  concerne  les  critères  de  jugement  fatal
(28 des  43  méta-analyses)  et  non-fatal  (28  des  40  méta-analyses).  Cependant,  pour  les  seuls
critères de  jugement  non-fatal,  la  différence  était  statistiquement  signiﬁcative  au  seuil  de  5  %
(p =  0,017).  Par  ailleurs,  l’absence  de  différence  statistiquement  signiﬁcative  dans  les  résul-
tats des  essais  entre  l’Europe  et  l’Amérique  du  nord  au  sein  des  méta-analyses  individuelles  a
indiqué qu’il  n’était  pas  possible  de  déterminer  pour  quel  type  d’intervention  ces  différences
intercontinentales  étaient  probablement  plus  prononcées  que  d’autres.
Conclusion.  —  Il  y  a  donc  certains  arguments  pour  conﬁrmer  la  théorie  que  comparativement
aux témoins,  les  interventions  sont  plus  favorables  dans  les  essais  cliniques  cardiovasculaires
conduits en  Europe,  et  non  en  Amérique  du  Nord,  lorsque  l’efﬁcacité  du  traitement  est  mesurée
en termes  de  critères  de  jugement  non-fatal.  Cependant,  la  preuve  globale  pour  des  différences
systématiques  entre  les  essais  cardiovasculaires  entre  l’Europe  et  l’Amérique  du  Nord  est  faible,
ce qui  est  surprenant  compte  du  volume  des  données  collectées.
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ackground
 question  that  often  arises  when  attempting  to  interpret
he  observed  efﬁcacy  of  treatments  within  clinical  trials,  is
hether  the  results  of  trials  conducted  in  one  country  can  be
ransferred  to  other  countries  or  continents.  The  assumption
t
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s  often  made  that  differences  in  the  efﬁcacy  of  treatments
etween  countries  (or  regions)  will  be  neither  negligible  nor
inor  and  therefore  cannot  be  overlooked  when  assessinghe  potential  beneﬁt  of  treatments  in  one  country  (or  region)
n  the  basis  of  trials  conducted  in  another  country  (or
egion)  [1—3].  However,  much  of  the  justiﬁcation  for  this
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sentiment  comes  from  anecdotal  evidence,  the  analysis  of  a
very  limited  pool  of  data  or  the  analysis  of  trial  results  that
have  not  been  obtained  through  a  full  systematic  review  [4].
A  popular  way  of  statistically  assessing  heterogeneity  in
treatment  effects  within  clinical  trials  is  to  perform  a  sub-
group  analysis  [5—7].  Therefore,  one  approach  to  assessing
differences  in  treatment  efﬁcacy  between  countries  is  to
perform  a  subgroup  analysis  of  a  multinational  trial  with
results  broken  down  according  to  country  [4,8—11].  How-
ever,  one  difﬁculty  with  such  a  strategy  is  that  the  data
produced  by  a  single  large  trial  may  not  be  sufﬁcient  to
reveal  such  differences,  even  when  they  are  genuinely  quite
large.  Also,  a  quick  literature  search  is  sufﬁcient  to  show
that  such  between-country  subgroup  analyses  are  rarely
published  and  the  authors  of  the  articles  concerned  may
not  be  willing  or  able  to  hand  over  the  required  information
when  it  is  requested.
An alternative  approach  would  be  to  compare  the  results
of  clinical  trials  conducted  in  one  country  with  the  results  of
similar  trials  conducted  in  another  country,  with  the  match-
ing  of  trials  determined  by  published  systematic  reviews;
this  is  the  approach  that  was  explored  in  the  present
study.  In  particular,  our  aim  was  to  assess  differences  in
the  results  of  randomized  controlled  trials  (RCTs)  between
Europe  and  North  America.  This  was  achieved  by  catego-
rizing  RCTs  within  published  systematic  reviews  according
to  the  countries  in  which  the  trials  were  conducted.  The
clinical  area  that  we  focused  on  was  cardiovascular  disease
(CVD);  this  specialty  was  chosen  due  to  the  rich  vari-
ety  of  interventions  that  are  commonly  used  to  treat  and
prevent  this  disease  (i.e.  interventions  ranging  from  the
use  of  drugs,  surgery  and  devices  to  changes  to  diet  and
lifestyle).
Two  major  obstacles  need  to  be  overcome  when  using
systematic  reviews  to  try  to  gauge  the  size  of  interna-
tional  differences  in  treatment  efﬁcacy:  these  differences
are  rarely  assessed  within  the  reviews  themselves;  and  a
comprehensive  list  of  the  countries  in  which  each  trial  within
any  given  review  was  conducted  is  rarely  provided.  More-
over,  it  is  often  the  case  that  the  country  in  which  a  trial
took  place  is  not  reported  even  in  the  article  that  originally
describes  the  principal  ﬁndings  of  the  trial.  Therefore,  with-
out  the  kind  of  thorough  search  for  country  information  that
was  carried  out  in  the  present  study,  it  would  be  very  difﬁ-
cult  for  a  clinician  or  researcher  to  form  a  general  picture
about  international  variations  in  clinical  efﬁcacy  over  a wide
range  of  different  interventions.
Methods
A  literature  search  of  Medline  and  the  Cochrane  Library  was
conducted  for  all  meta-analyses  of  RCTs  indexed  by  the  MESH
term  ‘cardiovascular  diseases’.  Meta-analyses  found  through
this  search  were  included  in  this  study  if  three  criteria  were
satisﬁed.  First,  the  meta-analyses  had  to  have  been  pub-
lished  in  the  9  years  between  January  2000  and  December
2008  for  the  Cochrane  Library  search  and  in  the  4  years
between  January  2005  and  December  2008  for  the  Medline
search.  A  longer  search  period  was  used  for  the  Cochrane
Library  as  it  is  a  database  that  generally  only  contains  meta-
analyses  that  are  the  most  up-to-date  and  of  the  highest
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uality  and  yet,  as  it  is  a  much  smaller  database  than  Med-
ine,  it  can  be  thoroughly  searched  without  requiring  an
xcessive  amount  of  resources.  The  articles  containing  the
eta-analyses  had  to  be  written  in  English.
Second,  the  patients  taking  part  in  the  RCTs  within  each
eta-analysis  had  to  be  adults.  With  regard  to  therapeutic
nterventions,  the  intervention  had  to  be  aimed  at  treat-
ng  a  problem  with  the  heart  or  a blood  vessel  in  the  chest
avity.  With  regard  to  preventive  interventions,  the  patients
oncerned  had  to  have  CVD  or  be  at  high  risk  of  CVD.
Third,  for  at  least  one  of  the  outcomes  reported,  results
ad  to  be  combined  over  at  least  two  trials  published  in  or
fter  1990  that  were  conducted  solely  in  Europe  and  at  least
wo  trials  published  in  or  after  1990  that  were  conducted
olely  in  North  America.
The  countries  in  which  trials  were  conducted  were  deter-
ined  on  the  basis  of  what  was  stated  in  the  articles  that
riginally  presented  the  trial  results.  If  such  country  infor-
ation  was  not  given,  then  the  country  (or  countries)  where
 trial  was  conducted  was  determined  by  contacting  the
uthors  directly  or  through  the  addresses  of  the  authors
hemselves,  but  only  if  the  authors  were  all  based  in  the
ame  country.  North  America  was  deﬁned  as  the  USA  and
anada.  Countries  belonging  to  Europe  were  determined
ccording  to  the  deﬁnition  of  Europe  used  by  the  statistics
ivision  of  the  United  Nations  [12].  Trials  published  before
990  were  excluded  in  order  to  focus  the  study  on  the  mea-
urement  of  international  differences  in  treatment  efﬁcacy
hat  may  presently  exist,  rather  than  the  measurement  of
uch  differences  in  the  past.  No  language  restriction  was
laced  on  articles  that  originally  presented  trial  results.
For  each  meta-analysis  satisfying  the  above  criteria,  the
ost  commonly  reported  fatal  endpoint  and  non-fatal  end-
oint  were  determined.  The  rule  used  to  achieve  this  was
hat  in  the  meta-analysis  concerned,  more  trials  were  com-
ined  over  that  fatal  (non-fatal)  endpoint  than  any  other
atal  (non-fatal)  endpoint.  For  example,  if  for  any  given
eta-analysis  there  were  two  non-fatal  endpoints  and  ﬁve
rials  were  combined  over  one  of  these  endpoints  while
our  trials  were  combined  over  the  other  endpoint,  then  the
ost  commonly  reported  non-fatal  endpoint  for  that  meta-
nalysis  would  be  deﬁned  as  the  former  endpoint.  Ties  were
ettled  by  choosing  the  endpoint  associated  with  the  highest
umber  of  patients.
Within  each  meta-analysis,  results  for  the  selected  end-
oints  were  separately  combined  within  North  America  and
ithin  Europe  to  give  individual  estimates  of  treatment  efﬁ-
acy  both  for  North  America  and  for  Europe  with  respect  to
oth  a  fatal  and  a  non-fatal  endpoint.  However,  this  was
nly  done  if  two  conditions  were  satisﬁed.  First,  in  relation
o  the  given  endpoint,  a  combined  estimate  of  efﬁcacy  over
ll  continents  was  presented  as  part  of  the  meta-analysis
oncerned.  Second,  there  were  results  from  at  least  two
rials  in  Europe  and  at  least  two  trials  in  North  America  for
he  given  endpoint.
The  ﬁrst  condition  ensured  that  this  study  carried  out
o  truly  new  meta-analyses,  but  instead  produced  only
ew  subgroup  breakdowns  for  existing  meta-analyses.  The
econd  condition  allowed  results  to  be  combined  using
 random-effects  model  [13].  This  is  more  than  just  a
inor  technical  issue,  as  combining  trial  results  using  a
andom-effects  rather  than  a  ﬁxed-effect  model  allows
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eterogeneity  between  trials  conducted  in  the  same  conti-
ent  or  region  to  be  taken  into  account.  For  example,  if
 trial  conducted  in  Europe  and  a  trial  conducted  in  North
merica  show  vastly  different  results,  it  would  be  impossi-
le  to  determine  without  further  information  whether,  for
nstance,  a  second  trial  conducted  in  Europe  would  show
imilar  results  to  the  one  conducted  in  North  America.
learly,  there  is  the  need  for  the  results  of  at  least  two
rials  conducted  in  a  given  region  in  order  to  take  account
f  such  heterogeneity  between  trials  within  that  region.
If  an  endpoint  was  event  based  and  event  rates  were
vailable,  then  trial  results  were  combined  over  relative
isks,  even  if  trial  results  were  reported  in  terms  of  odds
atios  in  the  meta-analysis  concerned.  However,  if  event
ates  were  not  available  and  the  meta-analysis  reported  trial
esults  in  terms  of  odds  ratios,  then  trial  results  were  com-
ined  over  odds  ratios.  In  other  words,  where  possible,  the
elative  risk  was  used  to  measure  treatment  efﬁcacy.
It  should  be  noted  that  although  fatal  and  non-fatal  end-
oints  were  allowed  to  vary  over  different  meta-analyses,
he  same  fatal  endpoint  (e.g.  cardiovascular  death  within
 year)  or  non-fatal  endpoint  (e.g.  non-fatal  myocardial
nfarction  within  1  year)  was  used  to  compare  trials  within
ny  given  meta-analysis.  Therefore,  since  comparisons  of
rial  results  for  Europe  and  North  America  were  only  con-
ucted  within  individual  meta-analyses,  a  large  variation
ver  different  meta-analyses  in  the  types  of  fatal  and
on-fatal  endpoints  being  analysed  was  of  only  secondary
oncern.
esults
he  literature  search  found  221  meta-analyses  that  satisﬁed
he  ﬁrst  and  second  inclusion  criteria.  Of  these  meta-
nalyses,  162  meta-analyses  did  not  have  the  required
umber  of  trials  published  in  or  after  1990  in  the  relevant
eographical  areas  for  the  third  criterion  to  be  satisﬁed.
lthough  the  exclusion  of  trials  published  before  1990  may
eem  to  be  quite  a  restrictive  criterion,  179  of  the  initially
dentiﬁed  221  meta-analyses  did  not  contain  any  trials  pub-
ished  before  1990.
In  summary,  59  meta-analyses  were  found  that  satisﬁed
ll  the  inclusion  criteria  of  the  study.  Of  these  meta-
nalyses,  47  meta-analyses  contained  a  sufﬁcient  number
f  trials  to  allow  separate  estimates  of  treatment  efﬁcacy
or  the  most  commonly  reported  fatal  endpoints  to  be  cal-
ulated  both  for  Europe  and  for  North  America.  Details
egarding  these  meta-analyses  are  given  in  Tables  1  and  2.
n  the  other  hand,  44  out  of  the  59  meta-analyses  included
n  the  study  contained  a  sufﬁcient  number  of  trials  to
llow  such  estimates  to  be  calculated  with  respect  to  the
ost  commonly  reported  non-fatal  endpoints.  These  meta-
nalyses  are  listed  in  Tables  3—5.
Although  there  are  no  two  meta-analyses  in  Tables  1—5
hat  are  based  on  exactly  the  same  set  of  trials,  it  is  clear
hat  some  of  the  meta-analyses  in  these  tables  addressed
imilar  clinical  questions  and  therefore  could  be  thought  of
s  ‘overlapping’  with  each  other.  For  meta-analyses  with
atal  endpoints,  there  are  29  meta-analyses  that  could
e  described  as  overlapping  [14—42].  By  ‘overlapping’,
t  is  meant  that  any  one  of  these  meta-analyses  shares
m
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ome  trial  results  with  at  least  one  other  of  these  meta-
nalyses,  to  the  extent  that  the  estimates  produced  by  these
eta-analyses  may  be  regarded  as  being  to  some  degree
ot  independent  of  one  another.  For  meta-analyses  with
on-fatal  endpoints,  there  are  23  such  overlapping  meta-
nalyses  [17,19,20,26—28,30—33,35,38—41,43—50].  There-
ore,  there  are  18  meta-analyses  with  fatal  endpoints
49—66]  and  21  meta-analyses  with  non-fatal  endpoints
15,22,25,42,52—55,57,59,61—64,66—72]  that  are  non-
verlapping  in  the  sense  just  outlined.
In  terms  of  what  was  in  each  case  the  most  commonly
eported  fatal  endpoint,  there  are  28  meta-analyses  where,
elative  to  the  control,  the  intervention  is  more  favoured
n  Europe  than  North  America,  15  meta-analyses  where  the
ntervention  is  more  favoured  in  North  America  than  Europe
nd  four  meta-analyses  where  the  intervention  and  control
roups  were  not  identiﬁed  (i.e.  one  treatment  group  was
imply  compared  with  another  treatment  group).  Using  a
inomial  test  under  the  null  hypothesis  that  the  efﬁcacy  of
nterventions  relative  to  controls  is  the  same  in  both  Europe
nd  North  America,  the  ratio  of  28  to  15  is  not  statistically
igniﬁcant  at  the  5%  level  (P  =  0.066).
Within  individual  meta-analyses,  the  difference  in  treat-
ent  efﬁcacy  between  Europe  and  North  America  in  terms
f  the  most  commonly  reported  fatal  endpoint  is  statisti-
ally  signiﬁcant  at  the  5%  level  in  one  meta-analysis  [30].
owever,  given  that  there  are  47  meta-analyses  with  fatal
ndpoints,  ﬁnding  one  difference  that  is  statistically  signif-
cant  at  the  5%  level  among  the  47  differences  assessed  is
ot  more  than  would  be  expected  by  random  chance  alone.
In  terms  of  what  was  in  each  case  the  most  commonly
eported  non-fatal  endpoint,  there  are  28  meta-analyses
here,  relative  to  the  control,  the  intervention  is  more
avoured  in  Europe  than  North  America,  12  meta-analyses
here  the  intervention  is  more  favoured  in  North  America
han  Europe  and,  again,  four  meta-analyses  where  the  inter-
ention  and  control  groups  were  not  identiﬁed.  Using  the
ame  binomial  test  as  outlined  earlier,  the  ratio  of  28  to  12  is
tatistically  signiﬁcant  at  the  5%  level  (P  =  0.017).  Therefore,
ith  respect  to  non-fatal  endpoints,  there  is  some  evidence
hat,  relative  to  controls,  interventions  are  more  favoured
n  Europe  than  North  America.
Within  individual  meta-analyses,  the  difference  in  treat-
ent  efﬁcacy  between  Europe  and  North  America  in  terms
f  the  most  commonly  reported  non-fatal  endpoint  is  sta-
istically  signiﬁcant  at  the  5%  level  in  two  meta-analyses
26,36].  However,  given  that  there  are  44  meta-analyses
ith  non-fatal  endpoints,  ﬁnding  that  two  meta-analyses
ive  statistically  signiﬁcant  results  at  the  5%  level,  in  the
anner  just  described,  again  does  not  demonstrate  the
xistence  of  intercontinental  differences,  as  this  is  not  a
reater  number  of  meta-analyses  than  would  be  expected
y  random  chance  alone.
In  trying  to  explain  the  result  that,  in  terms  of  non-
atal  endpoints,  interventions  appear  to  be  more  favoured
n  Europe  than  North  America,  the  possibility  that  this  result
ay  be  due  to  the  ‘double  counting’  of  trials  needs  to
e  assessed.  It  has  already  been  mentioned  that  among
eta-analyses  that  overlap  in  terms  of  the  clinical  ques-
ion  being  addressed,  some  trial  results  are  used  in  more
han  one  meta-analysis.  If,  among  these  trials,  a  higher  than
verage  proportion  of  interventions  are  more  favoured  in
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Table  1 Meta-analyses  with  fatal  endpoints:  efﬁcacy  measured  by  the  relative  risk.
Authors,  year,
Reference
Intervention  Control  Endpoint  No.  of  trials
(Europe/N.
Amer.)
Relative  risk  estimate  (95%  CI)  Best  regiona
(P  value  of
difference)
Europe  N.  Amer.
Hood  et  al.,  2004
[57]
Digitalis  for  CHF Placebo  All-cause  mortality 2/3  0.55  (0.12,  2.53) 0.99  (0.93,  1.06) Europe  (0.447)
Hooper  et  al.,
2004  [58]
Omega  3  fatty  acids  for
CVD
Placebo,  no
supplement  or
usual  diet
Cardiovascular
mortality
8/2  1.00  (0.73,  1.38) 0.25  (0.03,  2.24) N.  Amer.
(0.219)
Rees  et  al.,  2004
[62]
Psychological
interventions  for  CHD
Usual  care  or  no
intervention
Cardiovascular
mortality
2/6  0.70  (0.32,  1.52) 0.93  (0.67,  1.28) Europe  (0.505)
Amsallem  et  al.,
2005  [52]
Phosphodiesterase  III
inhibitors  for  HF
Placebo  Cardiovascular
mortality
2/5 1.55  (1.01,  2.37) 1.03  (0.72,  1.49) N.  Amer.
(0.160)
Krum  et  al.,  2005
[60]
Beta-blockers  without  ACE
inhibitors
Placebo  All-cause  mortality 2/3  0.93  (0.35,  2.47) 0.72  (0.45,  1.17) N.  Amer.
(0.641)
Rothberg  et  al.,
2005  [50]
Warfarin  plus  aspirin  after
MI  or  ACS
Aspirin  only  All-cause  mortality  3/2  0.93  (0.71,  1.22)  1.63  (0.33,  8.02)  Europe  (0.498)
Keeley  et  al.,
2006  [59]
Facilitated  PCI  for
ST-segment  elevation  MI
Primary  PCI Short-term  death
(all  cause)
8/2  1.07  (0.57,  1.99)  0.64  (0.08,  5.10)  N.  Amer.
(0.644)
Bravata  et  al.,
2007  [53]
PCIb CABG  surgeryb All-cause  mortality  7/3  0.61  (0.33,  1.13)  0.74  (0.41,  1.34)  Not  applic.
(0.652)
Dentali  et  al.,
2007  [55]
Combined  aspirin-oral
anticoagulant  therapy
Oral  anticoagulant
therapy  alone
All-cause  mortality 4/2  1.13  (0.88,  1.45) 0.61  (0.15,  2.41) N.  Amer.
(0.382)
Ezekowitz  et  al.,
2007  [56]
Implantable  cardioverter
deﬁbrillators  for  LVSD
Usual  care All-cause  mortality 2/3  0.82  (0.62,  1.08) 0.75  (0.63,  0.89)  N.  Amer.
(0.584)
Lafuente-
Lafuente  et  al.,
2007  [61]
Antiarrhythmics  after
cardioversion  of  AF
Placebo,  drugs  for
rate  control  or  no
treatment
All-cause  mortality  6/4  1.00  (0.78,  1.29)  1.43  (0.76,  2.70)  Europe  (0.301)
Wijeysundera
et  al.,  2007
[65]
Rescue  PCI  after  failed
ﬁbrinolytic  therapy  for  MI
Conservative
therapy
All-cause  mortality  2/2  0.68  (0.38,  1.22)  0.80  (0.04,  14.5)  Europe  (0.918)
De  Luca  et  al.,
2008  [54]
Early  IIb/IIIa  inhibitors  for
primary  PCI
Late  IIb/IIIa
inhibitors
All-cause  mortality  6/2  0.64  (0.33,  1.23)  1.19  (0.38,  3.67)  Europe  (0.357)
Schomig  et  al.,
2008  [63]
PCI-based  invasive
strategy  for  stable  CAD
Usual  medical
treatment
Cardiovascular
mortality
5/2  0.51  (0.26,  1.00) 0.92  (0.53,  1.59) Europe  (0.187)
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Table  1  (Continued)
Authors,  year,
Reference
Intervention  Control  Endpoint  No.  of  trials
(Europe/N.
Amer.)
Relative  risk  estimate  (95%  CI)  Best  regiona
(P  value  of
difference)
Europe  N.  Amer.
Whitlock  et  al.,
2008  [64]
Prophylactic  steroids  for
cardiopulmonary  bypass
Placebo  or
standard  care
In-hospital  mortality
(all  cause)
4/6  0.67  (0.22,  2.09)  0.65  (0.23,  1.86)  N.  Amer.
(0.967)
Wijeysundera
et  al.,  2008
[66]
Early  invasive  strategy
after  ﬁbrinolytic  therapy
for  MI
Ischaemia-guided
management
All-cause  mortality  3/2  0.58  (0.37,  0.94)  0.60  (0.16,  2.22)  Europe  (0.976)
Bosch  and
Marrugat,  2001
[17]
Glycoprotein  IIb/IIIa
inhibitors  for  PCI
Placebo  Death  within  30  days
(all  cause)
7/8  0.60  (0.32,  1.11)  0.72  (0.50,  1.06)  Europe  (0.598)
Andraws  et  al.,
2005  [15]
Antichlamydial  antibiotic
therapy  for  CAD
Placebo  All-cause  mortality  4/2  1.11  (0.70,  1.76)  1.08  (0.86,  1.35)  N.  Amer.
(0.898)
Clark  et  al.,  2005
[22]
Secondary  prevention
programmes  for  CAD
Usual  care  All-cause  mortality  17/10  0.81  (0.70,  0.94)  1.08  (0.83,  1.40)  Europe  (0.066)
Gabriel  et  al.,
2005  [26]
Hormone  replacement
therapy  for  preventing
CVD
Placebo  Cardiovascular
mortality
2/4 0.70  (0.41,  1.20)  1.11  (0.88,  1.39)  Europe  (0.130)
Holland  et  al.,
2005  [28]
Multidisciplinary
interventions  for  HF
Usual  care  All-cause  mortality  13/10  0.80  (0.61,  1.06)  0.82  (0.66,  1.01)  Europe  (0.922)
Mehta  et  al.,
2005  [32]
Routine  invasive  strategies
for  ACSb
Selective  invasive
strategiesb
All-cause  mortality  2/3  0.55  (0.17,  1.83)  1.18  (0.93,  1.51)  Not  applic.
(0.221)
Roccaforte  et  al.,
2005  [38]
Disease  management
programmes  for  HF
Usual  care  All-cause  mortality  12/13  0.85  (0.65,  1.11)  0.84  (0.67,  1.05)  N.  Amer.
(0.967)
Taylor  et  al.,
2005  [41]
Case  management
intervention  for  HF
Usual  care  All-cause  mortality  4/5  1.12  (0.85,  1.47)  0.75  (0.53,  1.05)  N.  Amer.
(0.074)
Abdulla  et  al.,
2006  [14]
CRT  for  LVSD  No  CRT  All-cause  mortality  5/3  0.69  (0.54,  0.87)  0.82  (0.66,  1.03)  Europe  (0.287)
Collet  et  al.,
2006  [24]
Systematic  early  PCI  after
ﬁbrinolytic  therapy
Ischaemia-guided
PCI
All-cause  mortality  2/2  0.52  (0.27,  1.00)  0.92  (0.24,  3.61)  Europe  (0.460)
Dong  et  al.,  2006
[25]
Thrombolytic  therapy  for
PE
Heparin  or  placebo
plus  heparin
All-cause  mortality  2/3  1.57  (0.45,  5.45)  0.91  (0.16,  5.32)  N.  Amer.
(0.620)
Gohler  et  al.,
2006  [27]
Disease  management
programmes  for  CHF
Standard  care  All-cause  mortality  12/15  0.79  (0.59,  1.06)  0.86  (0.71,  1.04)  Europe  (0.653)
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Table  1  (Continued)
Authors,  year,
Reference
Intervention  Control  Endpoint  No.  of  trials
(Europe/N.
Amer.)
Relative  risk  estimate  (95%  CI)  Best  regiona
(P  value  of
difference)
Europe  N.  Amer.
Roiron  et  al.,
2006  [39]
Drug-eluting  stents Bare-metal  stents All-cause  mortality 3/5  0.47  (0.06,  3.64) 0.98  (0.52,  1.84) Europe  (0.506)
Sedrakyan  et  al.,
2006  [40]
Off-pump  CABG  surgery On-pump  CABG
surgery
All-cause  mortality 9/3  0.92  (0.44,  1.93) 1.21  (0.41,  3.58) Europe  (0.677)
Clark  et  al.,  2007
[21]
Secondary  prevention
programmes  for  CHD
Usual  care All-cause  mortality 9/7  0.81  (0.70,  0.94) 0.99  (0.71,  1.38) Europe  (0.278)
Clark  et  al.,  2007
[23]
Remote  monitoring
programmes  for  chronic
HF
Usual  care All-cause  mortality 3/9  0.63  (0.43,  0.92) 0.78  (0.60,  1.00) Europe  (0.363)
Kastrati  et  al.,
2007  [29]
Sirolimus-eluting  stents Bare-metal  stents All-cause  mortality 5/2  1.00  (0.69,  1.44) 0.95  (0.65,  1.39) N.  Amer.
(0.837)
Labinaz  et  al.,
2007  [30]
Glycoprotein  IIb/IIIa
inhibitors  for  PCI
Placebo  or
standard  care
Death  within  30  days
(all  cause)
4/7  0.44  (0.21,  0.89)  0.72  (0.50,  1.04)  Europe  (0.221)
McAlister  et  al.,
2007  [31]
CRT  for  LVSD No  CRT All-cause  mortality 5/4  0.72  (0.57,  0.90) 0.83  (0.67,  1.03) Europe  (0.349)
Ramakrishnan,
2007  [36]
Thrombolytic  therapy  for
submassive  PE
Placebo  Short-term  death
(all  cause)
2/2  1.57  (0.45,  5.45) 0.70  (0.08,  6.44) N.  Amer.
(0.534)
Roberts  et  al.,
2007  [37]
Statin  monotherapy  for
CVD  in  older  adults
Placebo  All-cause  mortality  5/6  0.89  (0.84,  0.94)  0.97  (0.43,  2.18)  Europe  (0.828)
Ward  et  al.,  2007
[42]
Statins  for  CHD  Placebo  CHD  mortality  12/5  0.81  (0.74,  0.89)  0.82  (0.64,  1.05)  Europe  (0.900)
Moller  et  al.,
2008  [33]
Off-pump  CABG  surgery  On-pump  CABG
surgery
All-cause  mortality  14/4  0.96  (0.60,  1.53)  1.55  (0.72,  3.36)  Europe  (0.290)
Qayyum  et  al.,
2008  [35]
Routine  invasive  strategy
for  ACSb
Selective  invasive
strategyb
All-cause  mortality 4/3  0.74  (0.47,  1.16) 1.18  (0.93,  1.51) Not  applic.
(0.0728)
ACE: angiotensin-converting enzyme; ACS: acute coronary syndrome; AF: atrial ﬁbrillation; applic.: applicable; CABG: coronary artery bypass graft; CAD: coronary artery disease;
CHD: coronary heart disease; CHF: congestive heart failure; CI: conﬁdence interval; CRT: cardiac resynchronization therapy; CVD: cardiovascular disease; HF: heart failure; LVSD: left
ventricular systolic dysfunction; MI: myocardial infarction; N. Amer.: North America; PCI: percutaneous coronary intervention; PE: pulmonary embolism.
a Region where intervention performs best relative to the control (according to the data collected). The P value is for the difference in the estimates of the relative risk between Europe
and North America (under the null hypothesis of no difference).
b The intervention and control groups are not identiﬁed for these meta-analyses (i.e. one treatment group is simply compared with another treatment group).
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Table  2  Meta-analyses  with  fatal  endpoints:  efﬁcacy  measured  by  the  odds  ratio.
Authors,  year,
Reference
Intervention  Control  Endpoint  No.  of  trials
(Europe/N.
Amer.)
Odds  ratio  estimate  (95%  CI)  Best  regiona
(P  value  of
difference)
Europe  N.  Amer.
Abdulla  et  al.,
2006  [51]
ACE  inhibitors  for  LVSD  Placebo  All-cause  mortality  3/4  0.50  (0.19,  1.33)  0.87  (0.73,  1.02)  Europe  (0.280)
Patel  et  al.,  2006
[49]
Amiodarone  for  preventing
postoperative  AF
Placebo  or
routine
treatment
Death  within  30  days
(all  cause)
3/6  1.79  (0.34,  9.43)  0.82  (0.43,  1.59)  N.  Amer.
(0.397)
Cantor  et  al.,
2005  [18]
Immediate  PCI  after
thrombolytic  therapy
Delayed  PCI  Death  within
12  months  (all
cause)
3/2 0.55  (0.32,  0.92)  1.42  (0.73,  2.76)  Europe  (0.027)
Cho  and
Mukherjee,
2005  [19]
Hormone  replacement
therapy  for  preventing
CVD
Placebo  Cardiovascular
mortality
2/3 1.41  (0.26,  7.62)  1.10  (0.88,  1.38)  N.  Amer.
(0.776)
Choudhry  et  al.,
2005  [20]
Invasive  management
strategy  for  angina  and  MIb
Non-invasive
management
strategyb
All-cause  mortality  3/3  0.74  (0.40,  1.36)  1.22  (0.92,  1.61)  Not  applic.
(0.147)
Nordmann  et  al.,
2006  [34]
Drug-eluting  stents  for
CAD
Bare-metal  stents  Cardiovascular
death  within  1  year
4/4  0.85  (0.37,  1.97)  0.94  (0.50,  1.77)  Europe  (0.849)
Baker  and  Couch,
2007  [16]
Azithromycin  for
secondary  prevention  of
CAD
Placebo  All-cause  mortality  2/2  0.90  (0.22,  3.71)  0.94  (0.62,  1.42)  Europe  (0.952)
ACE: angiotensin-converting enzyme; AF: atrial ﬁbrillation; applic.: applicable; CAD: coronary artery disease; CI: conﬁdence interval; CVD: cardiovascular disease; LVSD: left ventricular
systolic dysfunction; MI: myocardial infarction; N. Amer.: North America; PCI: percutaneous coronary intervention.
a Region where intervention performs best relative to the control (according to the data collected). The P value is for the difference in the estimates of the odds ratio between Europe
and North America (under the null hypothesis of no difference).
b The intervention and control groups are not identiﬁed for these meta-analyses (i.e. one treatment group is simply compared with another treatment group).
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Table  3 Meta-analyses  with  non-fatal  endpoints:  efﬁcacy  measured  by  the  relative  risk.
Authors,  year,
Reference
Intervention  Control  Endpoint  No.  of  trials
(Europe/N.
Amer.)
Relative  risk  estimate  (95%  CI) Best  regiona
(P  value  of
difference)
Europe  N.  Amer.
Hood  et  al.,  2004
[57]
Digitalis  for  CHF Placebo  Clinical
deterioration
2/2 0.19 (0.02,  1.62) 0.34  (0.11,  1.07) Europe  (0.644)
Rees  et  al.,  2004
[62]
Psychological
interventions  for  CHD
Usual  care  or  no
intervention
MI  4/7 0.74  (0.54,  1.02) 0.76  (0.57,  1.02) Europe  (0.872)
Amsallem  et  al.,
2005  [52]
Phosphodiesterase  III
inhibitors  for  HF
Placebo  Worsening  heart
failure
3/6 1.52 (0.77,  3.01) 0.85  (0.63,  1.15) N.  Amer.
(0.130)
Andraws  et  al.,
2005  [15]
Antichlamydial  antibiotic
therapy  for  CAD
Placebo  MI  2/2 0.61  (0.26,  1.47) 1.03  (0.82,  1.29) Europe  (0.267)
Clark  et  al.,  2005
[22]
Secondary  prevention
programs  for  CAD
Usual  care Recurrent  MI 13/5 0.727  (0.60,  0.89) 0.733  (0.49,  1.10) Europe  (0.971)
Bleys  et  al.,  2006
[68]
Vitamin-mineral
supplements  for  CAD
Placebo  Restenosis 2/2 0.84  (0.34,  2.07) 0.97  (0.65,  1.44) Europe  (0.785)
Dong  et  al.,  2006
[25]
Thrombolytic  therapy  for
pulmonary  embolism
Heparin  or
placebo  plus
heparin
Major  hemorrhagic
events
2/2 0.61  (0.13,  2.96)  2.64  (0.44,  15.8)  Europe  (0.230)
Jovicic  et  al.,
2006  [70]
Self-management  strategy
for  HF
Usual
management
strategy
Hospital  readmission
within  1  year
2/3  0.73  (0.56,  0.95)  0.74  (0.58,  0.93)  Europe  (0.954)
Keeley  et  al.,
2006  [59]
Facilitated  PCI  for
ST-segment  elevation  MI
Primary  PCI  Short-term  major
bleeding
8/3  1.30  (0.83,  2.05)  2.60  (0.58,  11.7)  Europe  (0.388)
Bravata  et  al.,
2007  [53]
PCIb CABG  surgeryb Stroke  4/3  0.36  (0.09,  1.44)  0.40  (0.14,  1.13)  Not  applic.
(0.913)
Dentali  et  al.,
2007  [55]
Combined  aspirin-oral
anticoagulant  therapy
Oral
anticoagulant
therapy  alone
Major  bleeding 4/2 1.69  (0.94,  3.04) 1.28  (0.74,  2.23) N.  Amer.
(0.502)
Ho  et  al.,  2007
[69]
Intravenous  magnesium
for  acute  onset  AF
Placebo  or  other
antiarrhythmic
agent
Conversion  of  AF  to
sinus  rhythm
2/3 3.55  (1.21,  10.4)  1.07  (0.59,  1.95)  Europe  (0.056)
Lafuente-
Lafuente  et  al.,
2007  [61]
Antiarrhythmics  after
cardioversion  of  AF
Placebo,  drugs
for  rate  control
or  no  treatment
AF recurrence  11/6  0.70  (0.61,  0.81)  0.80  (0.67,  0.97)  Europe  (0.259)
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Table  3  (Continued)
Authors,  year,
Reference
Intervention  Control  Endpoint  No.  of  trials
(Europe/N.
Amer.)
Relative  risk  estimate  (95%  CI)  Best  regiona
(P  value  of
difference)
Europe  N.  Amer.
Ward  et  al.,  2007
[42]
Statins  for  CHD  Placebo  MI  13/4  0.67  (0.58,  0.77)  0.78  (0.66,  0.93)  Europe  (0.176)
De  Luca  et  al.,
2008  [54]
Early  IIb/IIIa  inhibitors  for
primary  PCI
Late  IIb/IIIa
inhibitors
Postprocedural  TIMI
3  ﬂow
6/2 1.05  (0.99,  1.11)  1.01  (0.91,  1.13)  Europe  (0.594)
Barth  et  al.,  2008
[67]
Psychosocial  smoking
cessation  help  for  CHD
Usual  care  Abstinence  from
smoking
6/7  1.22  (0.95,  1.57)  1.32  (1.13,  1.53)  N.  Amer.
(0.604)
Schomig  et  al.,
2008  [63]
PCI-based  invasive
strategy  for  stable  CAD
Usual  medical
treatment
MI  7/5  0.78  (0.46,  1.31)  1.11  (0.91,  1.37)  Europe  (0.209)
Whitlock  et  al.,
2008  [64]
Prophylactic  steroids  for
cardiopulmonary  bypass
Placebo  or
standard  care
New  onset  AF  3/7  0.84  (0.57,  1.25)  0.60  (0.46,  0.80)  N.  Amer.
(0.172)
Wijeysundera
et  al.,  2008
[66]
Early  invasive  strategy
after  ﬁbrinolytic  therapy
for  MI
Ischemia-guided
management
Major  bleeding  3/2  1.56  (0.57,  4.26)  1.24  (0.48,  3.24)  N.  Amer.
(0.744)
Bosch  and
Marrugat,  2001
[17]
Glycoprotein  IIb/IIIa
inhibitors  for  PCI
Placebo  30  days  urgent
revascularization
7/7  0.60  (0.38,  0.96)  0.48  (0.32,  0.71)  N.  Amer.
(0.453)
Aasbo  et  al.,
2005  [43]
Amiodarone  prophylaxis
for  cardiac  surgery
Placebo  Atrial  ﬁbrillation  or
ﬂutter
2/6 0.74  (0.39,  1.41)  0.66  (0.56,  0.78)  N.  Amer.
(0.721)
Bavry  et  al.,  2005
[46]
Sirolimus-eluting  stents
for  PCI
Bare-metal  stents  Stent-associated
thrombosis
2/2 0.25  (0.07,  0.90)  0.60  (0.14,  2.53)  Europe  (0.376)
Gabriel  et  al.,
2005  [26]
Hormone  replacement
therapy  for  preventing
CVD
Placebo  Stroke  4/2  1.71  (0.66,  4.44)  1.09  (0.88,  1.34)  N.  Amer.
(0.363)
Gillespie  et  al.,
2005  [48]
Amiodarone  prophylaxis
for  cardiothoracic  surgery
Placebo  Postoperative  AF  6/5  0.72  (0.56,  0.93)  0.65  (0.54,  0.78)  N.  Amer.
(0.506)
Holland  et  al.,
2005  [28]
Multidisciplinary
interventions  for  HF
Usual  care  Hospital  admission
(all  cause)
7/10  0.81  (0.63,  1.04)  0.88  (0.77,  1.00)  Europe  (0.579)
Mehta  et  al.,
2005  [32]
Routine  invasive  strategies
for  ACSb
Selective  invasive
strategiesb
Severe  angina  2/3  0.77  (0.66,  0.89)  0.93  (0.69,  1.24)  Not  applic.
(0.254)
Roccaforte  et  al.,
2005  [38]
Disease  management
programs  for  HF
Usual  care  All-cause
rehospitalization
10/12 0.79  (0.56,  1.11)  0.91  (0.72,  1.16)  Europe  (0.487)
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Table  3  (Continued)
Authors,  year,
Reference
Intervention  Control  Endpoint  No.  of  trials
(Europe/N.
Amer.)
Relative  risk  estimate  (95%  CI)  Best  regiona
(P  value  of
difference)
Europe  N.  Amer.
Rothberg  et  al.,
2005  [50]
Warfarin  plus  aspirin  after
MI  or  ACS
Aspirin  only MI  3/3 0.55  (0.42,  0.72) 0.65  (0.35,  1.19) Europe  (0.646)
Taylor  et  al.,
2005  [41]
Case  management
intervention  for  HF
Usual  care Hospital  readmission
due  to  HF
3/4 0.50 (0.26,  0.97) 0.68  (0.50,  0.91) Europe  (0.415)
Andreotti  et  al.,
2006  [44]
Aspirin  plus  warfarin  after
ACS
Aspirin  alone Major  bleeds 4/6 2.36  (1.53,  3.65) 1.53  (1.21,  1.92) N.  Amer.
(0.081)
Freemantle
et  al.,  2006
[47]
CRT  for  LVSD No  CRT Hospital  admission
due  to  HF
3/2 0.52 (0.41,  0.67) 0.67  (0.44,  1.05) Europe  (0.316)
Gohler  et  al.,
2006  [27]
Disease  management
programs  for  CHF
Standard  care Hospital  readmission
(all  cause)
12/16 0.75  (0.64,  0.90) 0.86  (0.77,  0.97) Europe  (0.196)
Roiron  et  al.,
2006  [39]
Drug-eluting  stents  Bare-metal  stents  Angiographic  binary
restenosis
3/5 0.12  (0.05,  0.28)  0.37  (0.23,  0.61)  Europe  (0.026)
Sedrakyan  et  al.,
2006  [40]
Off-pump  CABG  surgery  On-pump  CABG
surgery
Stroke  9/3  0.43  (0.18,  1.03)  1.22  (0.29,  5.22)  Europe  (0.229)
Labinaz  et  al.,
2007  [30]
Glycoprotein  IIb/IIIa
inhibitors  for  PCI
Placebo  or
standard  care
MI  within  30  days  4/7  0.87  (0.59,  1.30)  0.62  (0.50,  0.77)  N.  Amer.
(0.132)
McAlister  et  al.,
2007  [31]
CRT  for  LVSD  No  CRT  Hospital  admission
due  to  HF
2/3 0.53  (0.41,  0.68)  0.82  (0.55,  1.20)  Europe  (0.069)
Moller  et  al.,
2008  [33]
Off-pump  CABG  surgery On-pump  CABG
surgery
MI  14/4 0.75  (0.45,  1.27) 1.23  (0.40,  3.77) Europe  (0.437)
Qayyum  et  al.,
2008  [35]
Routine  invasive  strategy
for  ACSb
Selective  invasive
strategyb
MI  4/3  0.90  (0.49,  1.66)  0.87  (0.70,  1.08)  Not  applic.
(0.918)
ACS: acute coronary syndrome; AF: atrial ﬁbrillation; applic.: applicable; CABG: coronary artery bypass graft; CAD: coronary artery disease; CHD: coronary heart disease; CHF: congestive
heart failure; CI: conﬁdence interval; CRT: cardiac resynchronization therapy; CVD: cardiovascular disease; HF: heart failure; MI: myocardial infarction; N. Amer.: North America; PCI:
percutaneous coronary intervention; TIMI: thrombolysis in myocardial infarction.
a Region where intervention performs best relative to the control (according to the data collected). The P value is for the difference in the estimates of the relative risk between Europe
and North America (under the null hypothesis of no difference).
b The intervention and control groups are not identiﬁed for these meta-analyses (i.e. one treatment group is simply compared with another treatment group).
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Table  4  Meta-analyses  with  non-fatal  endpoints:  efﬁcacy  measured  by  the  odds  ratio.
Authors,  year,
Reference
Intervention  Control  Endpoint  No.  of  trials
(Europe/N.
Amer.)
Odds  ratio  estimate  (95%  CI)  Best  regiona
(P  value  of
difference)
Europe  N.  Amer.
Cho  and
Mukherjee,
2005  [19]
Hormone  replacement
therapy  for  preventing
CVD
Placebo  MI  2/3  0.70  (0.22,  2.19)  1.07  (0.84,  1.36)  Europe  (0.472)
Choudhry  et  al.,
2005  [20]
Invasive  management
strategy  for  angina  and  MIb
Non-invasive
management
strategyb
Hospital  readmission  2/2  0.45  (0.39,  0.53)  0.75  (0.60,  0.93)  Not  applic.
(0.0003)
Bagshaw  et  al.,
2006  [45]
Amiodarone  prophylaxis
for  cardiac  surgery
Placebo  or
routine
treatment
Postoperative  AF  5/7  0.47  (0.32,  0.69)  0.51  (0.41,  0.64)  Europe  (0.697)
Patel  et  al.,  2006
[49]
Amiodarone  for  preventing
postoperative  AF
Placebo  Bradycardia  4/3  1.24  (0.26,  5.85)  1.91  (1.05,  3.48)  Europe  (0.611)
AF: atrial ﬁbrillation; applic.: applicable; CI: conﬁdence interval; CVD: cardiovascular disease; MI: myocardial infarction; N. Amer.: North America.
a Region where intervention performs best relative to the control (according to the data collected). The P value is for the difference in the estimates of the odds ratio between Europe
and North America (under the null hypothesis of no difference).
b The intervention and control groups are not identiﬁed for these meta-analyses (i.e. one treatment group is simply compared with another treatment group).
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Table  5  Meta-analyses  with  non-fatal  endpoints:  efﬁcacy  measured  by  the  mean  difference.
Authors,  year,
Reference
Intervention  Control  Endpoint  No.  of  trials
(Europe/N.
Amer.)
Mean difference
(95%  CI)
Best  regiona
(P  value  of
difference)
Europe  N.  Amer.
Kelly  et  al.,
2004  [71]
Low  glycemic
index  diets  for
CHD
Other  diets  Total
cholesterol
7/3  −0.11
(−0.34,
0.12)
−0.06
(−0.35,
0.23)
Europe  (0.790)
Nolan  et  al.,
2008  [72]
Drug,
biobehavioral
and  exercise
therapies  for
CAD
Placebo  or
no  inter-
vention
Heart rate
variability
13/5 0.43  (0.25,
0.62)
0.46  (0.13,
0.79)
N.  Amer.
(0.893)
CAD: coronary artery disease; CHD: coronary heart disease; CI: conﬁdence interval; N. Amer.: North America.
a Region where intervention performs best relative to the control (according to the data collected). The P value is for the difference in
the estimates of treatment efﬁcacy (mean difference) between Europe and North America (under the null hypothesis of no difference).
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tEurope  than  North  America,  then  when  all  meta-analyses  are
aggregated  together,  there  will  be  disproportionately  strong
support  for  the  theory  that  interventions  are  favoured  more
in  Europe  than  North  America.
However,  in  terms  of  what  was  in  each  case  the  most
commonly  reported  non-fatal  endpoint,  the  percentage  of
meta-analyses  where,  relative  to  the  control,  the  inter-
vention  is  more  favoured  in  Europe  than  North  America
is  70%  both  for  meta-analyses  that  were  earlier  identi-
ﬁed  as  overlapping  and  for  those  that  were  identiﬁed  as
non-overlapping  (i.e.  in  both  cases  there  are  14  out  of  20
meta-analyses  where  the  intervention  is  more  favoured  in
Europe  than  North  America).  Therefore,  with  respect  to
non-fatal  endpoints,  there  is  no  evidence  that  the  over-
all  percentage  of  meta-analyses  where  the  intervention  is
more  favoured  in  Europe  than  North  America  (i.e.  70%;  28/40
meta-analyses)  has  been  inappropriately  inﬂated  due  to  the
type  of  double  counting  of  trial  results  discussed  above.
In  terms  of  what  was  in  each  case  the  most  commonly
reported  fatal  endpoint,  the  percentage  of  meta-analyses
where,  relative  to  the  control,  the  intervention  is  more
favoured  in  Europe  than  North  America  is  73%  for  meta-
analyses  that  were  earlier  identiﬁed  as  overlapping  (i.e.
19/26  meta-analyses),  but  only  53%  for  meta-analyses
that  were  identiﬁed  as  non-overlapping  (i.e.  9/17  meta-
analyses).  Therefore,  with  respect  to  fatal  endpoints,  there
is  some  evidence  that  the  large  (but  not  statistically  signif-
icant)  percentage  of  meta-analyses  where  the  intervention
is  more  favoured  in  Europe  than  North  America,  (i.e.  65%;
28/43  meta-analyses)  may  be  at  least  partially  due  to  the
type  of  double  counting  of  trial  results  discussed  above.
Discussion
There  is  no  evidence  in  this  study  to  support  the  theory
that,  for  fatal  endpoints,  there  are  systematic  differences
in  trial  results  between  Europe  and  North  America.  On  the
other  hand,  for  non-fatal  endpoints,  there  is  some  evidence
to  support  the  theory  that  relative  to  controls,  interventions
E
o
w
bre  more  favoured  in  trials  conducted  in  Europe  than  in
orth  America.  However,  it  is  not  possible,  on  the  basis
f  the  study  data,  to  determine  for  which  types  of  inter-
ention  these  intercontinental  differences  in  trial  results
or  non-fatal  endpoints  are  likely  to  be  more  pronounced
han  others.  This  is  because,  for  both  fatal  and  non-fatal
ndpoints,  the  proportion  of  times  that  within  individual
eta-analyses  the  difference  in  treatment  efﬁcacy  between
urope  and  North  America  is  statistically  signiﬁcant  at  the
%  level  is  not  more  than  would  be  expected  by  random
hance  alone.  The  lack  of  evidence  for  intercontinental  dif-
erences  produced  by  this  latter  analysis  may  be  surprising
iven  the  large  amount  of  data  that  has  been  collected.
The  potential  sources  of  bias  in  this  study  can  be  cat-
gorized  into  those  that  should  have  been  controlled  for
ithin  the  meta-analyses  that  form  the  raw  data  of  the  study
nd  those  that  generally  lie  outside  of  this  type  of  control.
ariations  in  treatment  regimen  and  patient  characteris-
ics  and  the  exclusion  of  poorly  conducted  trials  should  all
echnically  be  allowed  for  and  dealt  with  by  a  good-quality
eta-analysis,  although,  of  course,  there  may  be  many  deﬁ-
iencies  in  this  respect.  There  may  also  be,  for  example,  a
endency  in  some  countries  to  only  carry  out  RCTs  of  new
reatments  on  subgroups  of  patients  who  may  be  expected  to
eneﬁt  more  from  new  treatments  than  the  type  of  patients
ho  generally  participate  in  clinical  trials  in  other  countries.
A  type  of  bias  that  is  often  very  difﬁcult  to  allow  for
n  a  meta-analysis  is  publication  bias.  An  interpretation  of
he  results  of  this  study  in  terms  of  the  presence  of  this
ype  of  bias  would  be  that  trials  that  appear  in  systematic
eviews  are  more  likely  to  suffer  from  publication  bias  if
hey  were  conducted  in  Europe  rather  than  in  North  Amer-
ca.  The  theory  here  would  be  that  trial  results  that  either
avour  the  control  rather  than  the  intervention  or  are  not
trongly  favourable  towards  the  intervention  are  less  likely
o  be  published  if  the  trials  concerned  were  conducted  in
urope  rather  than  in  North  America.  However,  the  presence
f  publication  bias  in  a  meta-analysis  of  only  European  trials
ould  cause  as  much  of  a  problem  in  determining  what  is  the
est  treatment  in  a  European  context  as  it  would  in  trying
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o  use  the  same  results  to  decide  upon  the  best  treatment
n  a  North  American  context.  In  both  contexts,  we  need  to
lace  some  faith  in  published  trial  results  in  order  to  be  able
o  utilize  the  empirical  evidence  that  is  available.
Of  course  another  interpretation  of  the  results  of  this
tudy  is  that  potential  biases  within  the  source  data  did
ot  greatly  affect  these  results,  and  the  observation  that,
or  non-fatal  endpoints,  interventions  appear  to  be  more
avoured  in  trials  conducted  in  Europe  than  in  North  Amer-
ca  is  in  fact  a  consequence  of  the  existence  of  a  ‘genuine’
ntercontinental  difference.  In  other  words,  maybe  it  is  the
ase,  for  example,  that  European  health  care  policy  creates
n  environment  where,  in  comparison  with  North  America,
ew  and  innovative  treatments  are  more  likely  to  perform
etter  than  standard  treatments,  which,  of  course,  are  likely
o  be  the  control  treatments  in  RCTs.
A  reason  why  evidence  has  been  found  for  the  existence
f  intercontinental  differences  in  trial  results  with  regard  to
on-fatal  endpoints,  but  not  with  regard  to  fatal  endpoints,
s  that  real  differences  also  exist  for  fatal  endpoints,  it  is  just
hat  the  noise-to-signal  ratio  is  much  higher  when  estimating
fﬁcacy  in  terms  of  fatal  rather  than  non-fatal  endpoints  and
herefore  there  are  insufﬁcient  data  to  be  able  to  observe
hese  differences.  This  is  consistent  with  the  result,  already
oted,  that  in  terms  of  fatal  endpoints,  the  percentage  of
eta-analyses  where,  relative  to  the  control,  the  interven-
ion  is  more  favoured  in  Europe  than  in  North  America  is
5%,  although  the  difference  of  this  percentage  from  50%
s  not  quite  statistically  signiﬁcant  (P  =  0.066).  A  low  signal-
o-noise  ratio  may  also  explain  why  the  number  of  times
hat  intercontinental  differences  are  statistically  signiﬁcant
t  the  5%  level  within  individual  meta-analyses  is  not  more
han  would  be  expected  by  chance  alone  for  both  fatal  and
on-fatal  endpoints.
Another  reason  for  the  difference  in  the  results  between
atal  and  non-fatal  endpoints  is  that  judging  whether  a  non-
atal  endpoint  has  occurred  can  be  much  more  subjective
han  judging  whether  a  fatal  endpoint  has  occurred.  There-
ore,  if  there  is  a  tendency  for  poorly  regulated  trials  to  be
iased  in  favour  of  the  intervention  rather  than  the  control,
hen  this  bias  is  more  likely  to  reveal  itself  with  respect  to
 non-fatal  rather  than  a  fatal  endpoint.  This  provides  some
rounds  for  speculating  that  trials  in  Europe,  when  averaged
ver  all  countries  in  Europe,  may  not  be  as  well  regulated
s  trials  in  North  America.
The  main  strengths  of  this  study  were  the  amount  of  data
ollected  and  the  methodology  used  to  supplement  and  ana-
yze  this  data,  e.g.  using  published  systematic  reviews  in
rder  to  match  up  trials,  conducting  a  thorough  search  to
etermine  the  countries  in  which  trials  were  carried  out
nd  adjusting  for  heterogeneity  between  the  results  of  trials
onducted  in  the  same  continent.  In  particular,  the  potential
or  ﬁnding  spurious  international  differences  in  trial  results,
hich  may  have  been  found  in  other  studies  [3],  was  reduced
y  the  fact  that  a  random-effects  model  was  used  to  allow
or  this  latter  type  of  heterogeneity.  Also,  the  matching  up
f  trials  through  the  use  of  published  systematic  reviews
voided  the  type  of  pragmatic  strategies  for  comparing  trials
etween  countries  that  have  been  used  by  other  researchers
73,74].  The  task  of  performing  this  kind  of  study  in  the
uture  would  clearly  be  made  easier  if  researchers  prepar-
ng  the  results  of  trials  or  systematic  reviews  for  publication
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ere  willing  to  be  more  explicit  about  the  countries  in  which
rials  have  taken  place.
An  aspect  of  this  study  that  could  be  identiﬁed  as  being  a
eakness  is  that  the  huge  aggregation  of  data  made  it  difﬁ-
ult  to  identify  factors  that  may  be  causing  intercontinental
ifferences  and  to  determine  between  which  speciﬁc  regions
hese  differences  are  likely  to  be  more  pronounced  than  the
verall  average.  As  a  consequence,  it  should  be  pointed  out
hat  the  results  of  this  study  do  not  directly  provide  grounds
or  being  more  sceptical  about  claims  of  effectiveness  that
re  based  on  RCTs  conducted  in  speciﬁc  countries  in  Europe
ather  than  in  North  America,  e.g.  this  study  provides  no
irect  grounds  for  being  more  sceptical  about  RCTs  con-
ucted  in  the  UK  or  France  rather  than  in  the  USA.  However,
he  aggregation  of  data  was  necessary  in  order  to  combat
he  low  signal-to-noise  ratio  mentioned  above  and  to  be
ble  at  least  to  draw  some  kind  of  general  conclusions  about
ifferences  in  clinical  trials  between  regions.  Furthermore,
lthough  this  data  aggregation  was  performed  on  the  basis  of
 longer  search  period  for  the  Cochrane  Library  (2000—2008)
han  for  Medline  (2005—2008),  it  should  be  noted,  along  with
he  justiﬁcation  for  this  design  feature  made  in  the  Meth-
ds  section,  that  only  ﬁve  meta-analyses  [17,57,58,62,71]
ntered  the  present  study  as  a  result  of  the  search  of  the
ochrane  Library  from  2000  to  2004.
Another  potential  weakness  of  the  study  that  could  be
ighlighted  is  that  although,  unlike  other  studies,  this  study
ombined  information  from  many  different  trials,  it  did  not
ttempt  to  extract  patient-level  information  from  trials  that
ad  arms  in  both  Europe  and  North  America.  It  would  be
xpected  that  a  researcher  carrying  out  an  international
rial  would  at  least  check  for  differences  in  treatment  efﬁ-
acy  between  patients  based  on  the  country  where  they
articipated  in  the  trial.  However,  as  mentioned  previously,
t  is  very  much  the  exception  rather  than  the  rule  for  the
esults  of  these  analyses  to  be  published.  More  importantly,
he  present  study  was  designed  to  provide  information  to
elp  to  try  to  assess  what  the  likely  outcome  would  be  if  a
ompletely  new  trial  of  a  given  treatment  was  conducted  in
n,  as  yet,  untested  region  for  the  treatment  on  the  basis  of
he  results  of  older  trials  conducted  in  other  regions.  This
ssessment,  or  rather  the  deﬁnitiveness  of  this  assessment,
ould  determine  whether  it  is  worth  waiting  for  the  out-
ome  of  this  trial  before  approving  or  not  approving  the  use
f  the  treatment  in  the  region  concerned.
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